Vivo Capital
Funding rounds backed by Vivo Capital.
- Funding disclosed in full
- $595M
- Median round
- $110M
- Rounds in calculation
- 5
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| SonoThera Develops ultrasound-mediated nonviral genetic medicines | $125MSeries B | BiotechUnited States | 16 participantsAlexandria Venture InvestmentsARCH Venture PartnersARK InvestCureDuchenne VenturesDuquesne Family OfficeIllumina VenturesJohnson & Johnson Innovation – JJDCLeaps by BayerMedical Excellence CapitalOtsuka PharmaceuticalRA CapitalSymBiosisUCB Ventures SAVertex Ventures HCVida VenturesVivo Capital | ||
| Full-Life Technologies Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing | $150MSeries D+Debt | BiotechChina | |||
| Oricell Therapeutics Develops next-generation cell therapies for oncology and immunology | $110MPre-IPO | BiotechChina | |||
| Kinaset Therapeutics Develops inhaled therapies for severe respiratory diseases | $103MSeries B | BiotechUnited States | |||
| EpiBiologics Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo... | $107MSeries B | BiotechUnited States |